Baseline Characteristics of the 36 Patients
| Characteristic | All patients | Responders | Nonresponders |
| Sex | |||
| Male | 17 | 6 | 11 |
| Female | 19 | 6 | 13 |
| Age (y) at therapy | 64 (40–84) | 67.5 (44–84) | 63 (40–74) |
| Primary tumor type | |||
| Colorectal carcinoma | 21 | 8 | 13 |
| Breast carcinoma | 4 | 1 | 3 |
| Cholangiocarcinoma | 4 | 0 | 4 |
| Uveal melanoma | 4 | 1 | 3 |
| Neuroendocrine neoplasm | 1 | 1 | 0 |
| Pancreas carcinoma | 1 | 0 | 1 |
| Thymoma | 1 | 1 | 0 |
| Liver volume (mL) | 1,938 (1,155–3,842) | ||
| Metabolic tumor volume (mL) | 171 (5−1,993) | ||
| Administered activity (MBq) | 6,705 (3,676–12,897) | 7,632 (3,763–10,217) | 6,705 (3,676–12,897) |
| Previous treatment | |||
| Locoregional (liver) | 8 | 3 | 5 |
| Systemic | 34 | 11 | 23 |
| None | 2 | 1 | 1 |
| WHO status | |||
| 0 | 29 | 9 | 20 |
| 1 | 5 | 2 | 3 |
| Unknown | 2 | 1 | 1 |
| Extrahepatic disease at baseline | |||
| No | 26 | 8 | 18 |
| Yes | 10 | 4 | 6 |
Qualitative data are expressed as numbers; continuous data are expressed as median followed by range in parentheses.